On Monday 05/19/2025 the closing price of the Bio-Techne Corp share was $49.28 on BTT.
Compared to the opening price on Monday 05/19/2025 on BTT of $49.07, this is a gain of 0.43%.
Bio-Techne Corp's market capitalization is $6.37 B by 156.77 M shares outstanding.
Is Bio-Techne stock a Buy, Sell or Hold?
Bio-Techne stock has received a consensus rating of buy. The average rating score is and is based on 14 buy ratings, 8 hold ratings, and 0 sell ratings.What was the 52-week low for Bio-Techne stock?
The low in the last 52 weeks of Bio-Techne stock was 46.03. According to the current price, Bio-Techne is 107.58% away from the 52-week low.What was the 52-week high for Bio-Techne stock?
The high in the last 52 weeks of Bio-Techne stock was 83.55. According to the current price, Bio-Techne is 59.27% away from the 52-week high.What are analysts forecasts for Bio-Techne stock?
The 22 analysts offering price forecasts for Bio-Techne have a median target of 79.32, with a high estimate of 120.00 and a low estimate of 60.00. The median estimate represents a 62.43 difference from the last price of 49.52.Bio-Techne Stock Snapshot
46.55
Bid
100.00
Bid Size
52.22
Ask
100.00
Ask Size
5/20/2025
Date
3:59 PM
Time
0.00
Volume
49.28
Prev. Close
0.00
Open
7.72 B
Market Cap in USD
156.77 M
Number of Shares
156.77 M
Total Number of Shares
46.03
52 Week Low
83.55
52 Week High
49.52
0.32
Dividend in USD
0.45
Dividend Yield
68.54
P/E Ratio
98.87
Free Float in %
1.05
EPS in USD
13.08
Book Value per Share in USD
1.86
Cash Flow per Share in USD
Bio-Techne News More News
Historical Prices for Bio-Techne
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Bio-Techne Analyst Data
Total Analysts: 22
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 60.00
Median: 79.32
Highest: 120.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Bio-Techne Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 05/09/25 | UBS | Maintained Buy | $70 | |||
| 05/08/25 | RBC Capital Markets | Maintained Hold | $63 | |||
| 05/08/25 | The Benchmark Company | Maintained Buy | $75 | |||
| 05/08/25 | Stifel, Nicolaus & Co., Inc. | Maintained Buy | $60 | |||
| 03/18/25 | Evercore | Maintained Buy | $75 | |||
| 03/04/25 | Citigroup Corp. | Maintained Hold | $70 | |||
| 02/19/25 | Baird Patrick & Co | Downgraded to Hold | $68 | |||
| 02/06/25 | RBC Capital Markets | Maintained Hold | $80 | |||
| 05/22/24 | Citigroup Corp. | Downgraded to Hold | $85 | |||
| 05/02/24 | The Benchmark Company | Maintained Buy | $95 | |||
| 05/02/24 | Baird Patrick & Co | Maintained Buy | $81 | |||
| 04/18/24 | Deutsche Bank | Maintained Buy | $82 | |||
| 02/02/24 | Stephens Inc. | Maintained Buy | $87 | |||
| 02/02/24 | RBC Capital Markets | Maintained Hold | $75 | |||
| 02/02/24 | Stifel, Nicolaus & Co., Inc. | Downgraded to Buy | $65 | |||
| 12/07/23 | UBS | Maintained Buy | $80 | |||
| 11/02/23 | Stifel, Nicolaus & Co., Inc. | Maintained Buy | $65 | |||
| 11/01/23 | Citigroup Corp. | Maintained Buy | $80 | |||
| 11/01/23 | RBC Capital Markets | Maintained Hold | $83 | |||
| 09/12/23 | RBC Capital Markets | Maintained Hold | $86 | |||
| 08/28/23 | William Blair | Maintained Buy | ||||
| 08/18/23 | The Benchmark Company | Maintained Buy | $120 | |||
| 08/09/23 | Stephens Inc. | Maintained Buy | $100 |
Bio-Techne Estimates* in USD
| 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|
| Revenue | 1,218 | 1,290 | 1,399 | 1,657 |
| Dividend | 0.26 | 0.26 | 0.24 | - |
| Dividend Yield (in %) | 0.52 % | 0.53 % | 0.48 % | - |
| EPS | 1.91 | 2.09 | 2.37 | 3.03 |
| P/E Ratio | 25.87 | 23.63 | 20.78 | 16.26 |
| EBIT | 384 | 421 | 479 | 614 |
| EBITDA | 420 | 457 | 511 | 663 |
| Net Profit | 304 | 328 | 374 | 434 |
| Net Profit Adjusted | 304 | 328 | 374 | 434 |
| Pre-Tax Profit | 386 | 418 | 476 | 549 |
| Pre-Tax Profit Reported | 189 | 277 | 338 | 405 |
| EPS (Non-GAAP) ex. SOE | 1.91 | 2.09 | 2.37 | 3.03 |
| EPS (GAAP) | 0.87 | 1.25 | 1.84 | 2.02 |
| Gross Income | 851 | 925 | 1,025 | 1,190 |
| Cash Flow from Investing | -47 | -44 | -39 | - |
| Cash Flow from Operations | 259 | 322 | 280 | - |
| Cash Flow from Financing | -217 | -120 | -80 | - |
| Cash Flow per Share | 1.93 | 2.15 | 2.35 | - |
| Free Cash Flow | 222 | 279 | 241 | - |
| Free Cash Flow per Share | 1.39 | 1.78 | 1.54 | - |
| Book Value per Share | 12.92 | 14.48 | 16.89 | - |
| Net Debt | 173 | -58 | -352 | - |
| Research & Development Exp. | 99 | 104 | 111 | - |
| Capital Expenditure | 38 | 42 | 46 | - |
| Selling, General & Admin. Exp. | 443 | 435 | 429 | 492 |
| Shareholder’s Equity | 2,051 | 2,249 | 2,653 | - |
| Total Assets | 2,675 | 2,784 | 3,078 | - |
|
Previous Quarter ending 03/31/25 |
Current Quarter ending 06/30/25 |
Next Quarter ending 09/30/25 |
Current Year ending 06/30/25 |
Next Year ending 06/30/26 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | 12 | 9 | 13 | 12 |
| Average Estimate | - | 0.510 USD | 0.447 USD | 1.905 USD | 2.085 USD |
| Year Ago | - | 0.257 USD | 0.212 USD | 1.066 USD | - |
| Publish Date | - | 8/12/2025 | 11/4/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | 12 | 9 | 12 | 11 |
| Average Estimate | - | 317 USD | 303 USD | 1,218 USD | 1,290 USD |
| Year Ago | - | 306 USD | 289 USD | 1,159 USD | - |
| Publish Date | - | 8/12/2025 | 11/4/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Sales | 1,159.06 | 1,136.70 | 1,105.60 | 931.03 | 738.69 | 714.01 | 642.99 |
| Change of sales in % | 1.97 | 2.81 | 18.75 | 26.04 | 3.46 | 11.04 | 14.21 |
| Gross profit on sales | 773.07 | 769.82 | 723.00 | 604.45 | 456.59 | 428.64 | 410.49 |
| Gross profit on sales change in % | 0.42 | 6.48 | 19.61 | 32.38 | 6.52 | 4.42 | 16.21 |
| Operating income | 253.05 | 280.71 | 276.56 | 249.84 | 157.02 | 129.55 | 160.98 |
| Operating income change in % | -9.85 | 1.50 | 10.70 | 59.11 | 21.21 | -19.53 | 25.79 |
| Income before tax | 185.69 | 338.66 | 301.39 | 148.18 | 276.48 | 112.02 | 125.95 |
| Income before tax change in % | -45.17 | 12.37 | 103.40 | -46.41 | 146.82 | -11.07 | 12.50 |
| Income after tax | 168.07 | 285.19 | 271.93 | 140.32 | 229.07 | 95.97 | 126.04 |
| Income after tax change in % | -41.07 | 4.88 | 93.79 | -38.74 | 138.70 | -23.86 | 65.66 |
Balance Sheet in Mio. USD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 744.34 | 767.20 | 670.02 | 778.61 | 719.75 | 784.42 | 514.14 |
| Long-term liabilities per share | 3.70 | 4.05 | 3.15 | 4.02 | 3.99 | 4.50 | 2.89 |
| Equity | 2,068.85 | 1,966.52 | 1,701.01 | 1,571.23 | 1,381.19 | 1,165.59 | 1,079.06 |
| Equity change in % | 5.20 | 15.56 | 8.88 | 13.16 | 18.50 | 8.02 | 13.63 |
| Balance sheet total | 2,813.19 | 2,733.72 | 2,371.03 | 2,349.84 | 2,100.94 | 1,950.01 | 1,593.20 |
| Balance sheet total change in % | 2.91 | 15.30 | 0.90 | 11.85 | 7.74 | 22.40 | 2.25 |
Key Data in USD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 7.21 | 7.02 | 6.74 | 5.75 | 4.69 | 4.59 | 4.22 |
| P/E ratio (year end quote, basic EPS) | 68.54 | 46.33 | 52.30 | 129.89 | 45.42 | 84.49 | 44.67 |
| P/E ratio (year end quote, diluted EPS) | 68.54 | 46.33 | 52.30 | 129.89 | 45.42 | 84.49 | 44.67 |
| Dividend yield in % | 0.45 | 0.39 | 0.37 | 0.28 | 0.48 | 0.61 | 0.87 |
| Equity ratio in % | 73.54 | 71.94 | 71.74 | 66.87 | 65.74 | 59.77 | 67.73 |
| Debt ratio in % | 26.46 | 28.06 | 28.26 | 33.13 | 34.26 | 40.23 | 32.27 |
Bio-Techne Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Bohnen Shane | 04/02/2025 | 747.00 | 3,194.00 | 54.86 | Sell | No |
| Bohnen Shane | 04/02/2025 | 2,260.00 | 3,941.00 | n/a | Buy | No |
| Herr Amy E. | 02/13/2025 | 1,860.00 | 1,976.00 | 65.96 | Sell | No |
| Herr Amy E. | 02/13/2025 | 1,976.00 | 3,836.00 | 44.33 | Buy | No |
| Herr Amy E. | 02/02/2025 | 1,040.00 | 1,040.00 | n/a | Buy | No |
| Geist William | 01/31/2025 | 1,109.00 | 13,292.00 | 73.55 | Sell | No |
| McManus Matthew | 01/31/2025 | 1,642.00 | 2,978.00 | 73.55 | Sell | No |
| Geist William | 01/31/2025 | 3,320.00 | 14,401.00 | n/a | Buy | No |
| McManus Matthew | 01/31/2025 | 4,620.00 | 4,620.00 | n/a | Buy | No |
| Kelderman Kim | 01/26/2025 | 11,731.00 | 40,665.00 | 77.19 | Sell | No |
| Kelderman Kim | 01/26/2025 | 1,661.00 | 39,004.00 | 77.95 | Sell | No |
| Kelderman Kim | 01/26/2025 | 13,392.00 | 52,396.00 | 37.70 | Buy | No |
| Kelderman Kim | 10/31/2024 | 2,430.00 | 39,004.00 | 75.31 | Sell | No |
| Geist William | 10/31/2024 | 3,270.00 | 11,081.00 | 75.31 | Sell | No |
| Hippel James | 10/31/2024 | 6,475.00 | 106,610.00 | 75.31 | Sell | No |
| Hippel James | 10/31/2024 | 13,159.00 | 113,085.00 | n/a | Buy | No |
| Geist William | 10/31/2024 | 9,912.00 | 14,351.00 | n/a | Buy | No |
| VESSEY RUPERT | 10/23/2024 | 1,462.00 | 9,347.00 | n/a | Buy | No |
| KEEGAN JOSEPH D | 10/23/2024 | 1,462.00 | 13,771.00 | n/a | Buy | No |
| Seth Alpna | 10/23/2024 | 1,462.00 | 13,771.00 | n/a | Buy | No |
| BAUMGARTNER ROBERT V | 10/23/2024 | 1,462.00 | 44,863.00 | n/a | Buy | No |
| Bushman Julie L | 10/23/2024 | 1,462.00 | 7,135.00 | n/a | Buy | No |
| Nusse Roeland | 10/23/2024 | 1,462.00 | 44,559.00 | n/a | Buy | No |
| Klimovsky Judith V | 10/23/2024 | 1,462.00 | 2,142.00 | n/a | Buy | No |
| HIGGINS JOHN L | 10/23/2024 | 1,462.00 | 48,196.00 | n/a | Buy | No |
Bio-Techne Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2024 | Bio-Techne Corp | 0.32 | 0.45 | USD |
| 2023 | Bio-Techne Corp | 0.32 | 0.39 | USD |
| 2022 | Bio-Techne Corp | 0.32 | 0.37 | USD |
| 2021 | Bio-Techne Corp | 0.32 | 0.28 | USD |
| 2020 | Bio-Techne Corp | 0.32 | 0.48 | USD |
| 2019 | Bio-Techne Corp | 0.32 | 0.61 | USD |
| 2018 | Bio-Techne Corp | 0.32 | 0.87 | USD |
| 2017 | Bio-Techne Corp | 0.32 | 1.09 | USD |
| 2016 | Bio-Techne Corp | 0.32 | 1.14 | USD |
| 2015 | Bio-Techne Corp | 0.32 | 1.29 | USD |
| 2014 | Bio-Techne Corp | 0.31 | 1.33 | USD |
| 2013 | Bio-Techne Corp | 0.30 | 1.71 | USD |
| 2012 | Bio-Techne Corp | 0.28 | 1.50 | USD |
| 2011 | Bio-Techne Corp | 1.07 | 1.28 | USD |
| 2010 | Bio-Techne Corp | 1.03 | 1.79 | USD |
| 2009 | Bio-Techne Corp | 0.75 | 1.18 | USD |
| 2008 | Bio-Techne Corp | 0.00 | 0.00 | USD |
| 2007 | Bio-Techne Corp | 0.00 | 0.00 | USD |
| 2006 | Bio-Techne Corp | 0.00 | 0.00 | USD |
| 2005 | Bio-Techne Corp | 0.00 | 0.00 | USD |
| 2004 | Bio-Techne Corp | 0.00 | 0.00 | USD |
| 2003 | Bio-Techne Corp | 0.00 | 0.00 | USD |
| 2002 | Bio-Techne Corp | 0.00 | 0.00 | USD |
*Yield of the Respective Date
Bio-Techne Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 0.510 USD | Q4 2025 Earnings Release | 08/12/2025 |
| Earnings Report | 0.447 USD | Q1 2026 Earnings Release | 11/04/2025 |
| Earnings Report | 0.483 USD | Q2 2026 Earnings Release | 02/03/2026 |
| Earnings Report | 0.586 USD | Q3 2026 Earnings Release | 05/06/2026 |
Bio-Techne Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | 0.140 USD | Q3 2025 Earnings Release | 05/07/2025 |
| Earnings Report | 0.220 USD | Q2 2025 Earnings Release | 02/05/2025 |
| Earnings Report | 0.210 USD | Q1 2025 Earnings Release | 10/30/2024 |
| Annual General Meeting | 1.050 USD | Annual General Meeting | 10/24/2024 |
| Earnings Report | 0.250 USD | Q4 2024 Earnings Release | 08/07/2024 |
| Earnings Report | 0.310 USD | Q3 2024 Earnings Release | 05/01/2024 |
| Earnings Report | 0.170 USD | Q2 2024 Earnings Release | 02/01/2024 |
| Earnings Report | 0.310 USD | Q1 2024 Earnings Release | 10/31/2023 |
| Annual General Meeting | 1.760 USD | Annual General Meeting | 10/26/2023 |
| Earnings Report | 0.470 USD | Q4 2023 Earnings Release | 08/08/2023 |
| Earnings Report | 0.430 USD | Q3 2023 Earnings Release | 05/03/2023 |
| Earnings Report | 0.310 USD | Q2 2023 Earnings Release | 02/02/2023 |
| Earnings Report | 0.553 USD | Q1 2023 Earnings Release | 11/01/2022 |
| Annual General Meeting | 1.658 USD | Annual General Meeting | 10/27/2022 |
| Annual General Meeting | 1.658 USD | Annual General Meeting | 09/09/2022 |
| Earnings Report | 0.378 USD | Q4 2022 Earnings Release | 08/04/2022 |
| Earnings Report | 0.370 USD | Q3 2022 Earnings Release | 05/04/2022 |
| Earnings Report | 0.485 USD | Q2 2022 Earnings Release | 02/01/2022 |
Bio-Techne Profile
Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN. .
Moody’s Daily Credit Risk Score
Bio-Techne Management
| Name | Job |
|---|---|
| Robert V. Baumgartner | Chairman |
| James T. Hippel | Chief Financial Officer & Executive Vice President |
| Gary Latham | Chief Technology Officer & Vice President |
| Judith Klimovsky | Independent Director |
| Amy E. Herr | Independent Director |
| John L. Higgins | Independent Director |
| Julie L. Bushman | Independent Director |
| Rupert J. Vessey | Independent Director |
| Joseph D. Keegan | Independent Director |
| Alpna H. Seth | Independent Director |
| Kim Kelderman | President, Chief Executive Officer & Director |
| Matthew F. McManus | President-Diagnostics & Genomics Segment |
| William A. Geist | President-Protein Sciences Segment |
| Steven C. Crouse | SVP & GM-Analytical Solutions Division |
| Shane V. Bohnen | Secretary, Senior Vice President & General Counsel |
| Martin Wirtz | Senior VP-Strategy & Corporate Development |
| David Clair | VP-Investor Relations & Corporate Development |
| Qi Cheng | Vice President-Quality & Regulatory |